At Fluxion, we’re passionate about delivering cell-based and cell-free solutions that facilitate the transformation of research discoveries into new ways to diagnose and treat patients. By characterizing molecular and cellular mechanisms of disease, Fluxion’s platforms help bridge the translational medicine gap, enabling rapid advances in disease research, drug discovery, and the development of diagnostic tests.
Low signal-to-noise cfDNA-based liquid biopsies require improvements in sensitivity and specificity to provide the level of performance required for clinical utility. A common solution is the use of unique molecular identifiers (UMIs) to track individual molecules being amplified, but UMIs have their own limitations when used with real-world low DNA input samples.
This webinar will introduce ERASE-Seq, a novel approach to accurate calling for ultra-low MAF variants that does not require the use of UMIs.
The webinar will cover the following topics:
-The cfDNA analytical challenge- how low do we need to go to achieve traditional biopsy sensitivity? -Sources of error in liquid biopsy variant calling -Approaches to ultra-low MAF detection - LoFreq, UMIs, etc. -ERASE-Seq variant calling using Molecular Amplification Pools (MAPs) without UMIs -Adaption of ERASE-Seq to existing and custom panels -How to access and run the ERASE-Seq caller via a free trial
The following case studies will be presented:
-Applying ERASE-Seq to existing datasets -Using ERASE-Seq with your current panel for background correction or using MAPs -Applying ERASE-Seq to existing pre-validated NGS panels -Development and validation of a new NGS panel